MedKoo product information:

  FT-1050

Description of FT-1050: FT1050 is a small molecule drug candidate, currently being developed by Fate Therapeutics. FT1050 has shown promise in improving engraftment of administered HSCs. Fate Therapeutics has initiated a Phase 1b clinical trial for FT1050 in hematopoietic stem cell support in May 2009.  

Current developer:    Fate Therapeutics

FT1050 is the first drug candidate from Fate Therapeutics’ platform of Stem Cell Modulators (SCMs), small molecules and biologics that seek to modulate adult stem cells within the body to guide a desired outcome such as cell regeneration, healing or blocking cancer growth. In the case of HSCs, it has been demonstrated that stem cell pathways mediate the cells’ ability to home to the bone marrow and eventually repopulate the patient’s blood and immune system. Because FT1050 is believed to affect fundamental pathways present in all HSCs, FT1050 could improve the efficiency and success of treatment with HSCs from any source, including from bone marrow and peripheral blood.

FT1050 was discovered by Leonard Zon, M.D., director of the Stem Cell Program at Children’s Hospital Boston and a scientific founder of Fate Therapeutics and is part of an exclusive license granted to Fate by Children’s Hospital Boston and Massachusetts General Hospital. (source: Fate's website: http://www.fatetherapeutics.com/science-therapeutic-applications.php).